This site is intended for healthcare professionals only

In association with the Cardiorenal Forum

  • Latest Article

    Polypharmacy in CKD: a reason to review, not withhold, cardiorenal protection

    We are fortunate to have a rapidly expanding range of treatments for cardio-kidney-metabolic (CKM) disease, however it can be challenging to know whether add...

  • Canagliflozin and polypharmacy burden in CKD

  • Rituximab therapy compared to cyclophosphamide in ANCA-associated vasculitis

  • ASN Kidney health guidance on the cardiovascular-kidney-metabolic syndrome

  • ICU monitoring equipment and drip

    Dapagliflozin after cardiac surgery: reducing AKI or reducing the diagnosis of AKI?

  • Two surgeons during operation

    Dapagliflozin and acute kidney injury after cardiac surgery

  • Laboratory sample analyser

    Proteomic insights into dapagliflozin in CKD

Show all articles >
alt

For the latest news and articles
Sign up to Renal Review newsletters

Subscribe